First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to eval...